JP2009540852A - 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 - Google Patents

前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 Download PDF

Info

Publication number
JP2009540852A
JP2009540852A JP2009517228A JP2009517228A JP2009540852A JP 2009540852 A JP2009540852 A JP 2009540852A JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009540852 A JP2009540852 A JP 2009540852A
Authority
JP
Japan
Prior art keywords
nucleic acid
gene
antigen
sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540852A5 (enExample
Inventor
アインシュタイン，リチャード
ケイン，ケビン・ポール
パンド，マシュー・ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Publication of JP2009540852A publication Critical patent/JP2009540852A/ja
Publication of JP2009540852A5 publication Critical patent/JP2009540852A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009517228A 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 Pending JP2009540852A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81768606P 2006-07-03 2006-07-03
PCT/EP2007/056584 WO2008003656A2 (en) 2006-07-03 2007-06-29 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics

Publications (2)

Publication Number Publication Date
JP2009540852A true JP2009540852A (ja) 2009-11-26
JP2009540852A5 JP2009540852A5 (enExample) 2010-08-05

Family

ID=38537749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517228A Pending JP2009540852A (ja) 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用

Country Status (10)

Country Link
US (1) US20120141376A1 (enExample)
EP (1) EP2044216A2 (enExample)
JP (1) JP2009540852A (enExample)
KR (1) KR20090111307A (enExample)
CN (1) CN101506376A (enExample)
AU (1) AU2007271232A1 (enExample)
CA (1) CA2656140A1 (enExample)
IL (1) IL196184A0 (enExample)
WO (1) WO2008003656A2 (enExample)
ZA (1) ZA200900794B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016119897A (ja) * 2014-12-24 2016-07-07 ポステック アカデミー‐インダストリー ファウンデーション Ｅｎ２に特異的に結合するｄｎａアプタマーおよびこれの用途
JP2022530100A (ja) * 2019-04-25 2022-06-27 アクティニウム ファーマシューティカルズ インコーポレイテッド 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
JP6308954B2 (ja) * 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
JP2018526005A (ja) * 2015-09-02 2018-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 前立腺がんのげっ歯類モデル
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
US11410748B2 (en) * 2018-02-22 2022-08-09 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
CN111383757B (zh) * 2020-03-04 2023-08-25 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
JP2005519606A (ja) * 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012068484; ＥＳＴ３８９１８１　ＭＡＧＥ　ｒｅｓｅｑｕｅｎｃｅｓ，　ＭＡＧＯ　Ｈｏｍｏ　ｓａｐｉｅｎｓ　ｃＤＮＡ，　ｍＲＮＡ　ｓｅｑｕｅｎｃｅ，　ＧｅｎＢａｎｋ　Ａｃｃｅｓｓｉｏｎ　Ｎｏ．ＡＷ９７７０７２ , 2000 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016119897A (ja) * 2014-12-24 2016-07-07 ポステック アカデミー‐インダストリー ファウンデーション Ｅｎ２に特異的に結合するｄｎａアプタマーおよびこれの用途
US9429575B2 (en) 2014-12-24 2016-08-30 Postech Academy-Industry Foundation DNA aptamer specifically binding to EN2 (engrailed-2) and use thereof
JP2022530100A (ja) * 2019-04-25 2022-06-27 アクティニウム ファーマシューティカルズ インコーポレイテッド 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法

Also Published As

Publication number Publication date
US20120141376A1 (en) 2012-06-07
WO2008003656A2 (en) 2008-01-10
ZA200900794B (en) 2010-07-28
CA2656140A1 (en) 2008-01-10
AU2007271232A1 (en) 2008-01-10
WO2008003656A3 (en) 2008-03-20
CN101506376A (zh) 2009-08-12
IL196184A0 (en) 2009-09-22
KR20090111307A (ko) 2009-10-26
EP2044216A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
US7834163B2 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy
US20120141376A1 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20090053227A1 (en) Prostate Specific Genes and The Use Thereof in Design of Therapeutics
US6703221B1 (en) Notch receptor ligands and uses thereof
US20020051990A1 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
AU2003222103A8 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
CA2367125A1 (en) Reagents and methods useful for detecting diseases of the prostate
EP0939824A1 (en) Reagents and methods useful for detecting diseases of the breast
CA2267128A1 (en) Reagents and methods useful for detecting diseases of the prostate
US20080254031A1 (en) Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
US20060134668A1 (en) Methods for treating patients and identifying therapeutics
US20020068036A1 (en) Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
EP1206487A2 (en) Notch receptor ligands and uses thereof
US20040161775A1 (en) Gene SHINC-1 and diagnostic and therapeutic uses thereof
WO2002016939A2 (en) Methods of diagnosis of cancer and screening for cancer modulators
US20020061552A1 (en) Mammalian dishevelled-associated proteins
US20090098544A1 (en) Marker molecules associated with lung tumors
CA2279551A1 (en) Reagents and methods useful for detecting diseases of the lung
US20030198951A1 (en) Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20060089493A1 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030087245A1 (en) Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
US20050233353A1 (en) Methods and compositions for categorizing patients
CA2431313A1 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20030186232A1 (en) Human and non-human primate homologues of Nkd protein, nucleic acid sequences encoding, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130604